本周末，2025浦江创新论坛，人头攒动，思想碰撞。在今年同步举行的WeStart大会上，第一财经记者 围观全球科技新锐企业来这里现场推介交流，众多外籍与会者传递出了一个清晰的信号：上海，正凭借 其独特的创新生态，成为全球科技企业眼中不可错过的机遇之城。从瑞士、芬兰的尖端医疗设备，到斯 洛伐克的先进机械，不同国度的创新者们，不约而同地将目光投向了这片东方热土。更现场、更财经， 一探究竟！ ...

Group 1 - The core viewpoint is that Beijing E-Town is enhancing its foreign trade policies and promoting a new quality outbound strategy, as evidenced by the launch of the "Three Seas Action" to support enterprises in going global [1][3] - The E-Town Comprehensive Bonded Zone has officially started operations, achieving the fastest record in the country from application to establishment, providing new opportunities for enterprises [2] - The region has attracted 1,530 foreign-funded enterprises from 67 countries and regions, with 109 foreign R&D centers, indicating a shift from "in China" to "for China" and "for the world" [2] Group 2 - The export value in the first half of the year reached 31.43 billion RMB, representing a year-on-year increase of 16.9%, showcasing strong resilience in foreign trade [1] - Key enterprises such as Liangliang Vision, Wenyan Zhixing, and Galaxy Aerospace are making significant strides in international markets, with products like AR glasses and breakthroughs in autonomous driving [1] - The E-Town Comprehensive Bonded Zone is expected to enhance the global supply chain layout and accelerate the globalization of high-end medical equipment, as stated by the general manager of Raytai Medical [2]

Group 1: Technological Innovation in Private Enterprises - Private enterprises are becoming the backbone in breaking technological bottlenecks and driving innovation, particularly in key technology sectors [1] - The development of fiber optic preform technology has enabled the production of ultra-thin fibers that support high-speed internet communication, significantly reducing data transmission times [4][6] - Jiangsu Hengtong Marine Technology Co., Ltd. has laid over 110,000 kilometers of submarine cables, facilitating global connectivity for billions of people [10] Group 2: Advancements in Medical Technology - Domestic PET/CT technology has improved diagnostic efficiency, reducing scan times from 20-30 minutes to just 1-3 minutes, while increasing sensitivity by 40 times [15][17] - The approval of the photon counting spectral CT by United Imaging Healthcare enhances imaging resolution and aids in early detection of diseases [17][21] - Chinese medical device companies are expanding globally, with products now available in over 80 countries, contributing to the global healthcare sector [21] Group 3: Robotics and AI Integration - Robotics is becoming a key driver for industrial upgrading and innovation in China, with applications expanding across various sectors including logistics and healthcare [22] - The integration of multiple intelligences in robotics, such as operational, interactive, and motion intelligence, is enhancing their functionality and adaptability in everyday tasks [26] - The rapid development and deployment of humanoid robots indicate a significant acceleration in the robotics sector, with future advancements expected to improve their sensory and cognitive capabilities [28]

Investment Rating - The investment rating for the company is "Accumulate" [5][11]. Core Views - The company experienced a decline in revenue and net profit in the first half of 2025, with total revenue of 16.743 billion yuan, down 18.45% year-on-year, and net profit of 5.069 billion yuan, down 32.96% year-on-year. The gross margin decreased by 4.98 percentage points [1][5]. - International business showed resilience with revenue of 8.333 billion yuan in H1 2025, up 5.39% year-on-year, accounting for 49.76% of total revenue. Domestic revenue, however, fell to 8.411 billion yuan, down 33.37% year-on-year [1][2]. - The company plans to distribute a total cash dividend of 3.298 billion yuan for 2025, which represents 65.06% of the net profit for the first half of the year [2]. Summary by Sections Financial Performance - In Q2 2025, the company reported revenue of 8.506 billion yuan, a decrease of 23.77% year-on-year, and a net profit of 2.440 billion yuan, down 44.55% year-on-year, with a gross margin decline of 5.66 percentage points [1][5]. - The medical imaging business generated revenue of 3.312 billion yuan, down 22.51% year-on-year, with international revenue accounting for 62% [2]. - The life information and support business reported revenue of 5.479 billion yuan, down 31.59%, with international revenue share increasing to 67% [2]. Future Projections - Revenue projections for 2025-2027 are 36.730 billion yuan, 41.909 billion yuan, and 48.457 billion yuan, with year-on-year growth rates of 0.0%, 14.1%, and 15.6% respectively. Net profit projections are 12.219 billion yuan, 14.156 billion yuan, and 16.633 billion yuan, with growth rates of 4.7%, 15.8%, and 17.5% respectively [3][10].

02 在关键技术领域长期受制的背景下，民营企业成了打破技术瓶颈、推动创新突破的中坚力量。记者深入 苏州、上海、杭州等民营企业高地，亲眼见证了硬核科技的现实攻坚，推动创新成果深度融入实际应用 场景，让更多人共享科技进步和产业发展的红利。 01 光纤预制棒 从"0"到"1"的攻坚路 光纤预制棒通过高精度的拉丝技术，可以被拉成比头发丝还细的光纤。正是这些细如发丝的光纤，支撑 起了我们今天超高速的互联网通信。过去，使用传统光缆传输一部高清电影可能需要几分钟甚至更长时 间，而现在，依靠光纤技术，信息传输几乎可以在毫秒之间完成。 江苏亨通华海科技股份有限公司总经理 许人东：海底光缆实际上承载了全球95%以上国际间通信的容 量，是全球数字化、信息化非常重要的基础设施。存在的一些"卡脖子"的技术难题，第一是超长距离的 光电传输的技术难题，第二是万米水深的水密氢密的技术难题，第三是超高可靠性技术难题，因为在海 底通信系统里，我们一般要保证25年长期的可靠运行。 光纤是一种利用光信号进行信息传输的介质，随着传统玻芯光纤逼近物理极限，传输介质上的瓶颈成了 一个新的挑战。前不久，江苏一家企业研发生产的空芯光纤技术，为AI、人工智能、 ...

Company Overview - ResMed, founded in 1989 and headquartered in San Diego, specializes in medical equipment, particularly cloud-connectable CPAP machines for obstructive sleep apnea treatment [1] - The company operates in over 140 countries with more than 10,000 employees and has two main business units: Sleep and Respiratory Care, and Software as a Service (SaaS) [2] Business Model and Technology - ResMed's digital health network leverages cloud-connected devices to enhance patient outcomes and reduce healthcare costs through valuable insights generated from its hardware and SaaS data [3] Market Performance - The S&P/ASX200 Healthcare Index has returned -2.11% annually over the last 5 years, contrasting with an 8.69% return from the broader ASX 200 [4] - Healthcare spending is considered essential, leading to stable and consistent revenue streams, often referred to as 'sticky' revenue, which performed well during economic downturns [5] Growth Potential - Global healthcare spending, particularly in the US, is projected to grow at 7% per year from 2022 to 2027, reaching US$819 billion [6] - Sub-sectors like healthcare IT and SaaS are expected to see revenue growth exceeding 15% per year from 2024 to 2030 [7] Investment Trends - A Morgan Stanley survey indicates that over half of investors plan to increase their allocation to sustainable investments in 2024, positioning healthcare sectors favorably for attracting new capital [8] Valuation Metrics - ResMed shares currently have a price-sales ratio of 5.70x, below the 5-year average of 8.70x, suggesting potential undervaluation or increased sales [9][10]

Core Insights - Neuralink is set to launch a clinical trial in October aimed at helping individuals with language impairments convert "imagined language" into text or speech, with a goal of enabling healthy individuals to implant brain chips by 2030 [1][2] - The company has received FDA approval to use a device with research exemption in the upcoming trial, which focuses on enabling "thought communication" for patients who have lost their ability to speak due to illness or injury [1][4] - Neuralink has five additional clinical trials underway, starting in the U.S. and expanding to Canada, the UK, and the UAE [1] Market Potential - There are tens of millions of individuals globally with language barriers, particularly those suffering from ALS, strokes, and brain injuries, representing a significant potential market for Neuralink [2] - Beyond the Telepathy project, Neuralink is also developing products like Blindsight (vision restoration) and Deep (neurological disease treatment) [2] - The company aims to achieve an annual revenue of $1 billion by 2031, as stated in investor documents [2] Future Prospects - If the speech trial succeeds, Neuralink could capture opportunities in both the medical device and consumer human-computer interaction markets [3] - The company envisions that within three to four years, healthy individuals could have Neuralink implants, allowing them to communicate with AI models faster than speaking [3] - Neuralink was founded in 2016 and has raised approximately $1.3 billion, with a current valuation nearing $9 billion [3] Clinical Trial Background - Human trials are set to begin in 2024 after a previous FDA application was rejected in 2022 due to safety concerns; the company has since improved its design and received approval [4] - Currently, 12 subjects have implanted Neuralink chips, with over 15,000 hours of usage, allowing them to control cursors, browse the web, use social media, and play video games through thought [4] Investment Landscape - Neuralink's prospects have garnered significant attention from Silicon Valley and Wall Street, with the potential to enter a high-margin, high-tech barrier market upon FDA approval for clinical applications [7] - The company's expansion into healthy populations could redefine the future of human-computer interaction, although it also raises social and ethical concerns [7] - The duality of enthusiasm and apprehension in the capital markets may keep Neuralink in the spotlight for investors and public discourse in the coming years [7]

Core Viewpoint - GE Healthcare is reportedly exploring options to sell its stake in the Chinese market due to declining revenues, rising tariff costs, and increasing competition from local players [2][3] Financial Performance - GE Healthcare's global revenue for the year ending December 31, 2024, was $19.7 billion, a slight increase of 1% year-on-year [2] - The revenue from the Chinese market for GE Healthcare was $2.36 billion, representing a significant decline of 15% year-on-year, marking the largest drop since the company became independent in 2023 [2] - In the first half of 2025, GE Healthcare reported a further 3% decline in revenue from the Chinese market [3] Market Comparison - In the first half of 2025, Siemens Healthineers achieved revenue of €11.571 billion (approximately $13.39 billion), a year-on-year increase of 7% [3] - GE Healthcare's revenue for the same period was $9.78 billion, reflecting a 3% year-on-year growth [3] - Philips Healthcare reported revenue of €8.174 billion (approximately $9.46 billion), showing a year-on-year decline of 1.77% [3] - Siemens Healthineers was the only major player to experience growth in the Chinese market, with a 2.4% increase, while GE Healthcare and Philips saw declines of 2% and 11%, respectively [3]

【改写版】 过去三十年，欧洲人仿佛生活在童话世界里——每天工作不到8小时，每年带薪休假动不动就一个月，从摇篮到坟墓的福利保障让人羡慕。但揭开这层光鲜 外衣，你会发现欧洲的舒适生活其实是站在三个巨人肩膀上的：俄罗斯的能源、美国的枪杆子和中国的钱袋子。如今这三大支柱各怀心思，欧洲的好日子开 始摇摇欲坠。 北约体系下，6万美军常年驻守欧洲，美国人承担七成军费开支。德国军费占比仅1.5%，省下的钱全变成社会福利——瑞典父母能休480天带薪产假，芬兰 大学生每月白拿5500元补助。这种安全外包模式让欧洲安心搞经济，直到特朗普拍桌子要钱，欧洲人才发现没了美国保护伞，自己连一周防空都维持不了。 中国市场的黄金十年 当奔驰4S店在中国遍地开花时，欧洲企业赚得手软。大众每卖三辆车就有一辆销往中国，瑞士名表过半被中国买家收走。中国不仅是提款机，更是技术试 验场——空客A320对华报价比疫情前还低12%，西门子医疗设备三年降价25%。但2023年中国电动车反攻欧洲，市场份额暴涨至15%，光伏组件更拿下82% 市场，欧洲人突然发现学生变成了老师。 能源命脉握在俄罗斯手里 冷战结束后，欧洲就像染上能源鸦片般依赖俄罗斯。德国化工厂的烟囱 ...

Core Thesis - TransMedics Group, Inc. (TMDX) is viewed as significantly undervalued with a strong growth potential, particularly in the organ transplant sector, and is projected to exceed $200 per share by 2026 from current levels around $115–$120 [4][5]. Company Performance - As of September 15th, TMDX shares were trading at $114.29, with trailing and forward P/E ratios of 57.57 and 51.55 respectively [1]. - The company has demonstrated strong profitability with a 20% net margin in its most recent quarter, indicating potential for further margin expansion [3]. Market Context - TMDX has experienced share volatility, recently dropping from $140 to $105 due to typical Q3 seasonal softness and competitor-related news that do not materially impact its operations [2]. - The acquisition of OrganOx by Terumo for $1.5 billion, reflecting a valuation of over 20x sales, underscores the premium placed on high-growth medical device companies [2]. Growth Projections - TMDX is expected to grow revenues at over 30%, significantly outpacing the typical 10–15% growth of established competitors in the MedTech sector [3]. - The company is scaling its OCS program globally, which is expected to enhance its market position and revenue growth [5]. Management Confidence - The CEO of TransMedics has expressed a highly positive outlook for the company, emphasizing long-term growth and personally investing in the stock to demonstrate confidence [2][3]. - Shareholders are encouraged to focus on long-term growth rather than short-term volatility [3].